Lv1
40 积分 2023-01-06 加入
Impurity Characterization Across Drug Development Stages: Analytical Methodologies and Regulatory Perspectives
21小时前
已完结
Patient-Centric Drug Product Quality Specifications: a Convergence of Clinical and Nonclinical Considerations
3个月前
已完结
Industry perspective on a holistic container closure integrity approach to parenteral combination products
5个月前
已完结
Science- and Risk-Based Stability Strategies to Support Product Lifecycle Changes
8个月前
已完结
Risk Evaluation of N-Nitrosamines in Drug-Linker Intermediates Used To Generate Antibody–Drug Conjugates
9个月前
已完结
Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates
9个月前
已完结
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
9个月前
已完结
Risk Assessment and Control of N-Nitrosamines in Antibody–Drug Conjugates: Current Industry Practices
9个月前
已完结
Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices
9个月前
已完结
Development, validation, and implementation of a robust and quality control-friendly focused peptide mapping method for monitoring oxidation of co-formulated monoclonal antibodies
9个月前
已完结
皖公网安备34019202002308
